IP Library Granted Patent US 10,597,684
Granted Patent B2
US 10,597,684 · App. 15/108,259 · Granted Mar 24, 2020

Methods and organisms with increased carbon flux efficiencies

Inventors: Anthony P. Burgard (Bellefonte, PA); Robin E. Osterhout (San Diego, CA); Stephen J. Van Dien (Encinitas, CA); Priti Pharkya (San Diego, CA); Tae Hoon Yang (San Diego, CA); Jungik Choi (San Diego, CA)
Assignee: Genomatica, Inc.
C12P7/18C07K14/245C12N1/20C12N9/0036C12N9/0057C12N9/1205C12N9/16C12N9/52C12N9/88C12N9/93C12N15/52C12P7/42C12Y106/01002C12Y110/03C12Y207/0104C12Y301/00C12Y301/02C12Y301/02002C12Y304/21092C12Y401/01031C12Y401/01032
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,684
App. No.
15/108,259
Granted
Mar 24, 2020
Kind
B2
Abstract

The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate.

Claims (9)

1. A non-naturally occurring microbial organism comprising

(i) a genetic alteration that attenuates a cytochrome oxidase encoded by cydA or cydB, or an orthologous gene thereof, and a genetic alternation that increases expression of a NAD(P) transhydrogenase encoded by pntAB or an orthologous gene thereof; and

(ii) a genetic alternation that attenuates a succinyl-CoA synthetase encoded by sucCD or an orthologous gene thereof, and a genetic alternation that attenuates a CoA hydrolase encoded by yciA or an orthologous gene thereof.

2. The non-naturally occurring microbial organism of claim 1 , further comprising a metabolically engineered pathway for producing a bioderived compound from a TCA cycle intermediate or a TCA cycle substrate.

3. A non-naturally occurring microbial organism of claim 1 , wherein said microbial organism is selected from the group consisting of bacteria, yeast, fungus or other microorganism applicable to a fermentation process.

4. The non-naturally occurring microbial organism of claim 2 , wherein the yield of the bioderived compound is increased relative to the absence of said genetic alteration.

5. A method of producing a bioderived compound comprising culturing a non-naturally occurring microbial organism of claim 2 for a sufficient period of time under conditions sufficient to produce said bioderived compound.

6. The non-naturally occurring microbial organism of claim 2 , wherein said bioderived compound is selected from the group consisting of 4-hydroxybutyrate (4HB), 1,4-butanediol (1,4-BDO), 1,3-butanediol (1,3-BDO), polyhydroxylbutanoate (PHB), butadiene, adipate, 6-aminocaproate, caprolactam, methacrylic acid, isopropanol, long chain alcohols, hexamethylenediamene, methyl methacrylate, butanol, 3-butene-1-ol, 3-butene-2-ol and crotyl-alcohol.

7. A non-naturally occurring microbial organism of claim 3 , wherein said microbial organism is Escherichia coli.

Assignments (4)
SECURITY INTEREST Recorded Feb 10, 2026
From: GENOMATICA, INC.
To: AGAIN BIO APS
Reel/Frame 074708/0001 →
SECURITY INTEREST Recorded Dec 9, 2025
From: GENOMATICA, INC.
To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT
Reel/Frame 073915/0027 →
SECURITY INTEREST Recorded Jun 2, 2025
From: GENOMATICA, INC.
To: OXFORD FINANCE LLC
Reel/Frame 071471/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2016
From: OSTERHOUT, ROBIN E.; VAN DIEN, STEPHEN J.; BURGARD, ANTHONY P.; PHARKYA, PRITI; YANG, TAE HOON; CHOI, JUNGIK
To: GENOMATICA, INC.
Reel/Frame 040290/0891 →
Continuity (3)
Provisional Application 61921292 · Dec 27, 2013
Provisional Application 62013390 · Jun 17, 2014
Related Publication 20160326553A1 · Nov 10, 2016
Cited By (1)
US 12,435,346